Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.

摘要: Background & Aims: We report the first real-life results of sofosbuvir + daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients. Methods: The France REcherche Nord&Sud Sida-hiv Hepatites (ANRS) CO22 HEPATHER “Therapeutic options for B and C: A French cohort” is a multicentre observational cohort which aims to include 15,000 HCV- 10,000 HBV-infected patients. selected all participants (n = 768) with HCV who initiated sofosbuvir (400 mg/day) daclatasvir (60 mg/day) before October 1st 2014, or without ribavirin (1–1.2 g/day) duration 12 weeks 24 weeks. main endpoint criterion was sustained virological response at (SVR12), defined by absence detectable HCV-RNA after last treatment intake. Missing SVR12 measurements were imputed using SVR24 (n = 45), otherwise considered as failure (n = 18). Results: obtained 729/768 (95%) patients, ranging from 92% (12-week sofosbuvir + daclatasvir) 99% (24-week sofosbuvir + daclatasvir + ribavirin). rates did not significantly differ between 24-week (550/574 (96%)) 12-week (179/194 (92%); p = 0.0688) durations regimens (165/169 (98%)) (564/599 (94%); p = 0.0850). rate greater than 97% non-cirrhotic patients irrespective addition ribavirin. Among cirrhotic higher 24 regimen (423/444 vs. 105/119 (88%); p = 0.0054). Conclusion: associated high 1, an optimal 24 weeks number receiving too low adequately assess its impact.